MysDs enzyme for specifically producing mycosporine-like amino acids and preparation method of MysDs enzyme
By performing specific mutations on the 26 amino acid loop region of MysDs enzyme, its specificity in the production of shinorine and porphyra-334 is improved, and the problem of mixing by-products in MAAs production in the prior art is solved, achieving high purity and high purity Production of quality.
Patent Information
- Application Number
- CN202411226172.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
AI Technical Summary
When existing bioengineered microorganisms produce sporine-like amino acids (MAAs), the poor substrate specificity of MysDs enzyme leads to the formation of by-products, mainly a mixture of shinorine and porphyra-334, which makes it difficult to achieve specific production.
A new class of MysDs enzymes specifically producing sporophore amino acids has a loop region-specific mutation in its 26 amino acids, including the first and second MysDs enzymes, by changing the 17th amino acid in the loop region and The combination of the 25th amino acid, such as A and amino acids other than F or S and amino acids other than L, increases production specificity for shinorine or porphyra-334.
The biased production of shinorine or porphyra-334 by MysDs enzyme is realized, which improves the purity and quality of the product, and solves the problem of poor specificity of MAAs production by engineering and modified microbial microorganisms.
Smart Images

Figure CN119082053A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of mycosporin-like amino acid production, and in particular to a class of MysDs enzymes that specifically produce mycosporin-like amino acids and a preparation method thereof. Background Art
[0002] Ultraviolet (UV) rays are part of sunlight and can be divided into three types: UVA, UVB, and UVC. UVC is absorbed by the ozone layer in the Earth's atmosphere and does not reach the Earth's surface. However, both UVA (315-400nm) and UVB (280-315nm) rays can reach the Earth's surface and cause a range of harmful effects on the human body, including skin cancer, skin aging, immune system suppression, and eye damage.
[0003] Mycosporine-like amino acids (MAAs) are a class of naturally occurring compounds with UV-absorbing properties. Due to their biocompatibility and low environmental impact, they are considered more desirable sunscreen ingredients than traditional sunscreens such as zinc oxide and oxybenzone. MAAs also exhibit a variety of biological activities, including antioxidant, immunomodulatory, anti-aging, and anti-inflammatory properties. These properties make MAAs important raw materials for the cosmetics and skincare industries.
[0004] Traditional MAAs are primarily produced by extracting them from red algae (such as Porphyra), green algae, and certain species of cyanobacteria. This natural resource-based approach suffers from low yields and requires large quantities of natural algae to be harvested. Overharvesting can also put pressure on the ecosystem. Furthermore, naturally grown algae are subject to seasonal variations and geographic location, leading to variations in MAAs content and thus affecting the stability and consistency of MAAs extraction.
[0005] To address the challenges of traditional MAAs extraction methods, most researchers have focused on metabolically engineering microorganisms to produce MAAs, primarily in microorganisms such as Saccharomyces cerevisiae and Yarrowia lipolytica. The MAAs biosynthetic gene cluster comprises three conserved genes: mysA, encoding 2-demethyl 4-deoxygadusol synthase (DDGS); mysB, encoding a SAM-dependent O-methyltransferase (O-MT); and mysC, encoding an ATP-grasp enzyme. MysA and MysB catalyze the stepwise conversion of sedoheptulose 7-phosphate (S7P) from the pentose phosphate pathway (PPP) to 4-deoxygadusol (4-DG), the backbone of all MAAs. MysC then catalyzes the reaction of 4-DG with glycine to produce mycosporine-glycine (MG). In the patent document with patent number 202211236882.2, by introducing the xylose metabolic pathway, knocking out the TAL1 and Nqm1 genes to increase the amount of precursor S7P, and then inserting multiple copies of DDGS-OMT, the amount of 4-DG was increased, thereby providing a basis for constructing a strain (SC.L26) that produces MG, a direct precursor of MAAs, such as Figure 1 shown.
[0006] The gene cluster for MAAs also includes mysD, which encodes a homolog of D-alanine-D-alanine ligase (D-Ala-D-Ala-ligase), also known as MysDs. MysDs catalyzes the conjugation of amino acids with MG to produce different types of disubstituted MAAs, including shinorine (MG + L-serine) and porphyra-334 (MG + L-threonine). Therefore, through metabolic engineering, the introduction of genes such as mysA, mysB, mysC, and mysD into microorganisms can produce a variety of MAAs, such as shinorine, porphyra-334, and mycosporine-2-glycine. In the currently published patent documents, Sol Kim, Seoul (KR) in AU2019224876A1 and US2021230610A1 introduced the activities of 2-dehydro-3-deoxyphosphoheptonate aldolase, phosphoenolpyruvate synthase, and transketolase into microorganisms to increase the yield of MAAs produced by microorganisms. In addition, in patent document US2023064780A1, Ji-Sook Hahn, Seoul (KR) increased the precursor substance S7P by introducing the xylose pathway and knocking out the Tal gene, thereby increasing the yield of MAAs. However, the current bioengineered microorganisms that produce MAAs will produce a variety of disubstituted MAAs. The main reason is that the MysDs enzyme has poor substrate specificity, resulting in the formation of by-products, among which the MAAs are mainly a mixture of shinorine and porphyra-334.
[0007] Therefore, how to improve the specificity of MAAs produced by engineered microorganisms remains a research focus and difficulty in the field of MAAs production technology. Summary of the Invention
[0008] The purpose of this application is to provide a new class of MysDs enzymes that specifically produce mycosporin-like amino acids and a preparation method thereof.
[0009] This application adopts the following technical solutions:
[0010] The first aspect of the present application discloses a MysDs enzyme that specifically produces mycosporin-like amino acids. The MysDs enzyme contains a loop region of 26 amino acids, and the loop region is of the following two types:
[0011] Class I MysDs enzymes: The 25th amino acid in the loop region is A, and the 17th amino acid is any amino acid except F; or, the 25th amino acid in the loop region is S, and the 17th amino acid is L. Class I MysDs enzymes are used to specifically produce shinorine;
[0012] The second type of MysDs enzyme: the 25th amino acid in the loop region is S, and the 17th amino acid is any amino acid except L; alternatively, the 25th amino acid in the loop region is A, and the 17th amino acid is F; the second type of MysDs enzyme is used to specifically produce porphyra-334.
[0013] It should be noted that the key to this application is the discovery that the 26-amino acid loop region of the MysDs enzyme can effectively determine the specificity of mycosporin-like amino acid production, that is, the specific production of shinorine or porphyra-334. Compared with the 43-45 amino acid sequence loop region discovered by Ji-Sook HAHN, Seoul (KR)'s team, the loop region of this application is shorter and easier to edit and manipulate. Furthermore, this application's research found that within the 26-amino acid loop region of this application, the first type of MysDs enzyme can specifically produce shinorine, and the second type of MysDs enzyme can specifically produce porphyra-334.
[0014] That is, the 25th amino acid in the 26-amino acid loop region of the present application is mutated to A, and the 17th amino acid is any amino acid except F; or the 25th amino acid in the loop region is mutated to S, and the 17th amino acid is mutated to L; such MysDs enzymes or mutants, i.e., the first class MysDs enzymes, can specifically produce shinorine. The 25th amino acid in the 26-amino acid loop region of the present application is mutated to S, and the 17th amino acid is any amino acid except L; or the 25th amino acid in the loop region is mutated to A, and the 17th amino acid is mutated to F; such MysDs enzymes or mutants, i.e., the second class MysDs enzymes, can specifically produce porphyra-334.
[0015] In the present application, specifically producing shinorine or porphyra-334 means that the MysDs enzyme can preferentially produce shinorine or porphyra-334; for example, the first type of MysDs enzyme can specifically produce shinorine means that, compared with the prior art, most or more than 50% of the products obtained using the first type of MysDs enzyme are shinorine, and the rest are still a small part of porphyra-334. Therefore, the first type of MysDs enzyme is said to have a shinorine preference and can specifically produce shinorine; similarly, the second type of MysDs enzyme can specifically produce porphyra-334 means that most or more than 50% of the products obtained using the second type of MysDs enzyme are porphyra-334, and the rest are still a small part of shinorine. Therefore, the second type of MysDs enzyme is said to have a porphyra-334 preference and can specifically produce porphyra-334.
[0016] It should also be noted that the MysDs enzyme of this application contains a 26-amino acid loop region because the present application's research has found that this 26-amino acid loop region effectively determines the specificity of the MysDs enzyme in producing mycosporin-like amino acids; furthermore, the 26-amino acid loop region is defined to better localize the 17th and 25th amino acids within the loop region. In principle, based on the 26 amino acids of this application, several amino acids can be added as needed or designed to form a longer loop region. As long as the mutation types of the 17th and 25th amino acids specified in this application are met, specific production of shinorine or porphyra-334 can be achieved.
[0017] In one implementation of the present application, the loop region is at least one of SEQ ID NO.1 to SEQ ID NO.22; wherein, the loop region of the first type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.1 to SEQ ID NO.10; the loop region of the second type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.11 to SEQ ID NO.22.
[0018] It should be noted that the loop regions of the sequences shown in SEQ ID NO. 1 to SEQ ID NO. 22 are only the 22 loop regions specifically used in the examples of this application to specifically produce mycosporin-like amino acids. Furthermore, these 22 loop regions effectively confirmed and verified that when the 25th amino acid in the loop region is A and the 17th amino acid is any amino acid other than F, or when the 25th amino acid in the loop region is S and the 17th amino acid is L, shinorine can be specifically produced; and when the 25th amino acid in the loop region is S and the 17th amino acid is any amino acid other than L, or when the 25th amino acid in the loop region is A and the 17th amino acid is F, porphyra-334 can be specifically produced.
[0019] In one implementation of the present application, the first type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.23 to SEQ ID NO.32; the second type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.33 to SEQ ID NO.44.
[0020] It should be noted that the first type of MysDs enzymes represented by sequences shown in SEQ ID NO. 23 to SEQ ID NO. 32 and the second type of MysDs enzymes represented by sequences shown in SEQ ID NO. 33 to SEQ ID NO. 44 are MysDs enzymes corresponding to the loop regions of the sequences shown in SEQ ID NO. 1 to SEQ ID NO. 22 specifically used in the examples of the present application. These MysDs enzymes effectively confirmed and verified the effects of mutations in the 17th and 25th amino acids on the specific production of mycosporin-like amino acids by the MysDs enzymes, i.e., when the 25th amino acid is A and the 17th amino acid is any amino acid except F, or when the 25th amino acid in the loop region is S and the 17th amino acid is L, shinorine can be specifically produced; when the 25th amino acid in the loop region is S and the 17th amino acid is any amino acid except L, or when the 25th amino acid in the loop region is A and the 17th amino acid is F, porphyra-334 can be specifically produced.
[0021] It can be understood that as long as the mutation rules of the above 17th amino acid and 25th amino acid are met, specific production of shinorine or porphyra-334 can be achieved, not limited to the 22 loop regions of the sequences shown in SEQ ID NO.1 to SEQ ID NO.22 specified in this application, nor limited to the 22 MysDs enzymes of the sequences shown in SEQ ID NO.23 to SEQ ID NO.44.
[0022] The second aspect of the present application discloses a nucleic acid encoding the MysDs enzyme of the present application.
[0023] The third aspect of the present application discloses a recombinant plasmid containing the nucleic acid of the present application.
[0024] It should be noted that the recombinant plasmid containing the nucleic acid of the present application can be transformed into an engineered bacterium to express the MysDs enzyme of the present application, thereby achieving the specific production of shinorine or porphyra-334.
[0025] The fourth aspect of the present application discloses a microorganism transformed with the recombinant plasmid of the present application.
[0026] It should be noted that the microorganism transformed with the recombinant plasmid of the present application is actually an engineered bacterium used to express the MysDs enzyme of the present application to achieve the specific production of shinorine or porphyra-334.
[0027] In one implementation of the present application, the microorganism is a recombinant organism, and the recombinant organism is an organism that can produce 4DG using xylose, which is obtained by integrating xylose metabolism genes, DDGS genes, and OMT genes into the genome of the organism after knocking out endogenous genes; wherein the knocked-out endogenous genes include the TAL1 gene and the Nqm1 gene, the xylose metabolism genes include the xyl1 gene, the xyl2 gene, and the xyl3 gene, and the insertion site of at least one of the xyl1 gene, the xyl2 gene, and the xyl3 gene is the his3 site.
[0028] Preferably, among the xylose metabolism genes, the pTDH3 promoter is used to drive the expression of the xyl1 gene, the pPGK1 promoter is used to drive the expression of the xyl2 gene, and the pTEF2 promoter is used to drive the expression of the xyl3 gene.
[0029] Preferably, the organism or engineered bacteria of the present application is yeast.
[0030] It should be noted that the recombinant organism of the present application is actually the recombinant organism constructed in the previous patent No. 202211236882.2 of the inventor of the present application; it can be understood that on the basis of the recombinant organism constructed in patent 202211236882.2, combined with the first class MysDs enzyme or the second class MysDs enzyme of the present application, specific production of shinorine or porphyra-334 can be achieved. In addition, the advantageous effects of the recombinant organism in patent 202211236882.2 can also be obtained, that is, while improving the specificity of mycosporin-like amino acid production, the yield of mycosporin-like amino acids can be increased. Therefore, all technical contents regarding the construction of recombinant organisms in patent 202211236882.2 are cited in this application.
[0031] The fifth aspect of the present application discloses the use of the MysDs enzyme, the nucleic acid, the recombinant plasmid or the microorganism of the present application in the specific production of mycosporin-like amino acids.
[0032] It should be noted that the microorganisms of the present application are engineered bacteria capable of expressing the MysDs enzyme of the present application, and therefore can be used for the specific production of shinorine or porphyra-334; of course, according to different design or production requirements, the engineered bacteria can also be subjected to a series of modifications, such as using the improved recombinant organisms in patent 202211236882.2. As for the nucleic acids and recombinant plasmids of the present application, they can be used as raw materials to prepare engineered bacteria expressing the MysDs enzyme of the present application.
[0033] The sixth aspect of the present application discloses a method for specifically producing mycosporin-like amino acids, comprising using the MysDs enzyme, nucleic acid, recombinant plasmid or microorganism of the present application to specifically produce shinorine or porphyra-334.
[0034] One implementation of the present application specifically includes using the first type of MysDs enzyme among the MysDs enzymes of the present application, or the nucleic acid encoding the first type of MysDs enzyme of the present application, or the recombinant plasmid containing the nucleic acid encoding the first type of MysDs enzyme of the present application, or the microorganism transformed with the recombinant plasmid containing the nucleic acid encoding the first type of MysDs enzyme of the present application, to specifically produce shinorine; or using the second type of MysDs enzyme among the MysDs enzymes of the present application, or the nucleic acid encoding the second type of MysDs enzyme of the present application, or the recombinant plasmid containing the nucleic acid encoding the second type of MysDs enzyme of the present application, or the microorganism transformed with the recombinant plasmid containing the nucleic acid encoding the second type of MysDs enzyme of the present application, to specifically produce porphyra-334.
[0035] It should be noted that the method for producing mycosporin-like amino acids of the present application can specifically produce shinorine or porphyra-334, solving the problem of poor specificity of engineered microorganisms in producing mycosporin-like amino acids; and, combined with the improved recombinant organisms in patent 202211236882.2, the production of mycosporin-like amino acids can be further increased.
[0036] The beneficial effects of this application are:
[0037] The MysDs enzyme of the present application has good substrate specificity, can effectively improve the production specificity of shinorine or porphyra-334, improve the purity and quality of a single mycosporin-like amino acid in the final product, and solve the specificity problem of engineering microorganisms to produce mycosporin-like amino acids. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 is the three-dimensional conformation predicted by Np.MysD and Nl.MysD in the examples of this application;
[0039] Figure 2 This is the conformation of Np.MysD after alignment with 2DLN in the examples of this application;
[0040] Figure 3 This is the molecular docking result of Np.MysD and Nl.MysD in the examples of this application;
[0041] Figure 4 Schematic diagram of the process of engineering yeast strains in the examples of this application;
[0042] Figure 5 This is the test result of the change in MAAs production after replacing the loop region and site-directed mutagenesis of Np.MysD and Nl.MysD in the examples of this application;
[0043] Figure 6 These are the test results of MAAs production of MysDs in different modes in the examples of this application. DETAILED DESCRIPTION
[0044] In a recently published article, Ji-Sook HAHN, Seoul (KR) and their team discovered that MysDs has a 43-45 amino acid sequence loop that determines the specific production of MAAs (DOI: 10.1016 / j.ymben.2023.05.009). However, this application further studies the specific production of MAAs. First, this application shortens the loop sequence to 26 amino acids through bioinformatics analysis and experimental verification. Second, through site-directed mutagenesis, the role of two amino acid residues in the loop is determined. Finally, through homologous sequence alignment and heterologous expression of other uncharacterized MysDs in nature, it is discovered that two key amino acid patterns determine the law of specific production. Determining the identity of these two key residues can predict the products that MysDs enzymes preferentially produce. This provides guidance for screening uncharacterized MysDs enzyme candidates and lays the foundation for rationally modifying MysDs enzymes to connect to new amino acid substrates.
[0045] Specifically, the MysDs enzyme of the present application that specifically produces mycosporin-like amino acids contains a loop region of 26 amino acids, and the loop region is of the following two types:
[0046] Class I MysDs enzymes: The 25th amino acid in the loop region is A, and the 17th amino acid is any amino acid except F; or, the 25th amino acid in the loop region is S, and the 17th amino acid is L. Class I MysDs enzymes are used to specifically produce shinorine;
[0047] The second type of MysDs enzyme: the 25th amino acid in the loop region is S, and the 17th amino acid is any amino acid except L; alternatively, the 25th amino acid in the loop region is A, and the 17th amino acid is F; the second type of MysDs enzyme is used to specifically produce porphyra-334.
[0048] Metabolic engineering of Saccharomyces cerevisiae strains:
[0049] Using CRISPR-Cas9 to knock out and insert genes, a strain capable of producing MG, a direct precursor of MAAs, was engineered. This section references the recombinant organism constructed in patent 202211236882.2, and all technical details regarding the construction of the recombinant organism in that patent are incorporated into this application.
[0050] Structure prediction and molecular docking:
[0051] The three-dimensional structure of the MysDs enzyme was predicted using tools such as ColabFold and AutoDock Vina, and molecular docking was performed. The goal was to understand how the active site of the MysD enzyme interacts with the substrate and thus infer the key residues that determine substrate preference.
[0052] Sequence alignment and structure analysis:
[0053] Sequence alignments of multiple MysD enzymes were combined with structural analysis to identify conserved or variant residues that may be associated with substrate preference. Structural alignments and sequence analysis narrowed the focus to a few potential key residues.
[0054] Experimental verification:
[0055] Using site-directed mutagenesis, we altered predicted key residues and observed the effects of these mutations on product specificity. We then characterized multiple MysD enzymes with similar patterns to uncover patterns in key amino acid patterns.
[0056] Product concentration determination:
[0057] Liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and other techniques were used to measure the concentrations of MAAs produced by different MysDs enzyme variants. The product composition of different variants was analyzed to assess the improvement in product specificity.
[0058] The present invention is further described in detail below by means of specific examples. The following examples are only provided to further illustrate the present invention and should not be construed as limiting the present invention. Unless otherwise specified, the methods for constructing plasmids or strains in this application are based on the molecular cloning protocol (4th edition).
[0059] Example 1
[0060] In this case, we found that the MysDs enzyme determines the omega-loop sequence for the specific production of MAAs, which involves the following steps:
[0061] 1) MysDs structure prediction: MysD from Nostoc punctiforme PCC 73102 (Np.MysD, WP_012411846) and MysD from Nostoc linckia NIES-25 (Nl.MysD, BAY79928) were selected as examples of specific production of shinorine and porphyra-334. Their amino acid sequences were used to perform three-dimensional structure prediction on the Alphafold2 server ColabFold (AlphaFold2.ipynb-Colab (google.com)). The generated models were ranked according to their pLDDT scores, and the top-ranked PDB model was selected for subsequent analysis. The results of the top-ranked PDB model are shown in Figure 2. Figure 1 shown. Figure 1 In the figure, the green structure diagram in Figure A is the predicted three-dimensional conformation of Np.MysD, and the red structure diagram in Figure B is the predicted three-dimensional conformation of Nl.MysD.
[0062] 2) Domain and substrate binding site prediction: The PDB models of Np.MysD and Nl.MysD were aligned with the crystal structure of Escherichia coli D-Ala-D-Ala-ligase (PDB ID: 2DLN) using PyMOL software. The conformation of Np.MysD after alignment with 2DLN is shown in Figure 2. Figure 2 shown. Figure 2 In the figure, Np.MysD is green, 2DLN is blue, and magnesium ion is yellow. The docking pocket is near the magnesium ion. Based on the alignment results, the characteristic α+βATP-grasp folding structure was identified and the binding site of MG was predicted to be located between one and two Mg 2+ Binding sites adjacent to The long cubic box is adjacent to the ATP-grasp fold structure.
[0063] 3) Molecular docking: In this example, we first dock an ADP molecule with two Mg 2+ Ion docking was performed into the structure of the enzyme. The enzyme and ligand files were then preprocessed using AutoDockTools 1.5.7 (ADT). The two MysDs models were used as receptors, and the corresponding intermediate molecules were used as ligands. The ligands were docked into the active site of the enzyme using Autodock Vina 1.2.0. Among them, the two intermediate molecules, the intermediate molecule corresponding to the Np.MysD model receptor is mycosporine-glycine (MG) plus a phosphate group and L-serine; the intermediate molecule corresponding to the Nl.MysD model receptor is mycosporine-glycine (MG) plus a phosphate group and L-threonine, as shown in Figure 2. Figure 4 As shown in Figure A of , please refer to patent 202211236882.2 for details. The ligand conformation with the highest affinity score was selected for subsequent analysis. The results are as follows Figure 3 As shown in Figures A and B of the , detailed operation methods can be found in PMID: 27077332. We hypothesized that residues within 8 angstroms of the docking intermediate in Np.MysD and Nl.MysD are involved in substrate recognition and determine product specificity. We found that all active site residues are clustered in a 26-amino acid loop region, as shown in Figure 2. Figure 3 As shown in Figure C. Figure 3 Figure A shows the docking result between Np.MysD and MG-SER; Figure B shows the docking result between Nl.MysD and MG-Thr; Figure C shows the loop sequence; light blue represents the loop region, rose red represents the key amino acid site, yellow represents magnesium ion, and lavender represents ADP.
[0064] 4) Expression verification of loop mutant: In the early stage, we have constructed an engineered strain of Saccharomyces cerevisiae (yeast strain L6, abbreviated as SC.L26) that can produce the precursor substance MG. The specific construction method of the yeast strain L6 is as follows: Figure 4 As shown, specific reference is made to patent 202211236882.2, and all contents regarding the construction of Saccharomyces cerevisiae engineered strains in the patent are incorporated into this example. Figure 4 Figure A shows the engineered metabolic pathway for the biosynthesis of disubstituted MAAs. Knocking out the Tal1 gene and its homologous gene Nqm1 weakens the conversion of S7P to the unwanted F6P. Introducing the xylose utilization pathway increases the production of S7P. Double knock-in of mysA and mysB and introduction of mysC (green) complete the transformation of the MG production engineered strain SC.L26. Figure B shows the engineering steps of the Saccharomyces cerevisiae strain.
[0065] Np.MysD and Nl.MysD were inserted into the link024 plasmid to generate recombinant plasmids. In this example, the plasmids containing Np.MysD were constructed, labeled link024-Np.MysD; the plasmid containing Nl.MysD was constructed, labeled link024-Nl.MysD; the recombinant plasmid containing the 26-amino acid loop of Np.MysD was replaced with the loop of Nl.MysD, labeled link024-Np.MysD-Nl.Loop; and the recombinant plasmid containing the 26-amino acid loop of Nl.MysD was constructed, labeled link024-Nl.MysD-Np.Loop. Each of the four recombinant plasmids was transformed into SC.L26. The strain was cultured in SC-U medium for two days. The fermentation broth was frozen and thawed twice, and the supernatant was centrifuged. The supernatant was filtered through a 0.22 μm filter membrane and then subjected to LC-MS detection. Each sample was tested three times.
[0066] All nucleic acid fragments were synthesized by BGI and inserted into the link024 plasmid. The recombinant plasmid was transformed into SC.L26 by preparing 500 ng of the recombinant plasmid, adding it to SC.L26 competent cells, and then transforming it into the SC.L26 strain using the lithium acetate method (refer to the molecular cloning manual). The transformed yeast were screened on SC-U solid medium. Strains that successfully transformed with the plasmid would grow on SC-U plates, while those that did not would not.
[0067] In this example, the 26-amino acid loop of Np.MysD, namely Np.loop, is the sequence shown in SEQ ID NO.1, and the 26-amino acid loop of Nl.MysD, namely Nl.loop, is the sequence shown in SEQ ID NO.9.
[0068] SEQ ID NO.1:RNYADKLQQTDDGDLHLTAKDNIKAW
[0069] SEQ ID NO.9:RTYADKLKKTDDGSLGFAAKGNNKSW
[0070] The Np.MysD enzyme is the sequence shown in SEQ ID NO.21, and the Nl.MysD enzyme is the sequence shown in SEQ ID NO.31.
[0071] SEQ ID NO.21:
[0072] MPVLNILHLVGSAHDKFYCDLSRLYAQDCLAATADPSLYNFQIAYITPDRQWRFPDSLSREDIALTKPIPVFDAIQFLTGQNIDMMLPQMFCIPGMTQYRALFDLLKIPYIGNTPD IMAIAAHKARAKAIVEAAGVKVPRGELLRQGDIPTITPPAVVKPVSSDNSLGVVLVKDVTEYDAALKKAFEYASEVIVEAFIELGREVRCGIIVKDGELIGLPLEEYLVDPHDKPI RNYADKLQQTDDGDLHLTAKDNIKAW ILDPNDPITQKVQQVAKRCHQALGCRHYSLFDFRIDPKGQPWFLEAGLYCSFAPKSVISSMAKAAGIPLNDLLITAINETLGSNKKVLQN
[0073] SEQ ID NO.31:
[0074] MPVLRILHLVGSAQDDFYCDLSRLYAQDCLAAMAELPYDSAIAYITPDGQWRFPRSLSREDIAQAKPMPVSEAIEFIAAQNIDIVLPQMFCIPGMTYYRALFDLLEIPYIGNTPD LMAITAHKARTKAIVEAAGVKVPRGEVLRRGDVPTITPPVVIKPVSSDNSLGVTLVKDAAEYEAALEKAFEHGDEAIVETFIEGREVRCGIIVKDGELIGLPLEEYLIDSQEKPI RTYADKLKKTDDGSLGFAAKGNNKSW ILDPNDPITQKVQEVAKKCHQALGCRHYSLFDFRIDSQGQPWFLEAGLYCSFAPKSVISSMAKAVGIPLNELLTIAIAETLGSNKYSDRISVVEINEPSKTPRKERELSQMI
[0075] The loop of Np.MysD was replaced with the loop of Nl.MysD, i.e., the double-underlined portion of the sequence in SEQ ID NO.21 was replaced with the sequence shown in SEQ ID NO.9; the loop of Nl.MysD was replaced with the loop of Np.MysD, i.e., the double-underlined portion of the sequence in SEQ ID NO.31 was replaced with the sequence shown in SEQ ID NO.1.
[0076] link024-Np.MysD is the sequence shown in SEQ ID NO.43.
[0077] SEQ ID NO.43:
[0078] gtgagtaaggaaagagtgaggaactatcgcatacctgcatttaaagatgccgatttgggcgcgaatcc tttattttggcttcaccctcatactattatcagggccagaaaaaggaagtgtttccctccttcttgaattgatgtt accctcataaagcacgtggcctctttatcgagaaagaaattaccgtcgctcgtgatttgtttgcaaaaagaacaaaa ctgaaaaaacccagacacgctcgacttcctgtcatcctattgattgcagcttccaatttcgtcacacaacaaggtc ctagcgacggctcacaggttttgtaacaagcaatcgaaggttctggaatggcgggaaagggtttagtaccacatgc tatgatgcccactgtgatctccagagcaaagttcgttcgatcgtactgttatctctctctttcaaacagaattgt ccgaatcgtgtgacaacaacagcctgttctcacacactcttttcttctaaccaagggggtggtttagtttagtaga acctcgtgaaacttacatttacatatatataaacttgcataaattggtcaatgcaagaaatacatatttggtcttt tctaattcgtagtttttcaagttcttagatgctttctttttctcttttttacagatcatcaaggaagtaattatct actttttacaacaaatataaaacaagatc
[0079] SEQ ID NO.43 is the nucleic acid sequence of link024-Np.MysD. The horizontal underline is the promoter pPGK1, the wavy line is the terminator tPGK1, and the non-underlined region is the CDS region of Np.MysD. All MysDs sequences in this application are inserted into the link024 plasmid and have the same promoter and terminator; therefore, the subsequent nucleic acid sequences only show the CDS sequence of MysDs.
[0080] The CDS sequence of Nl.MysD in the link024-Nl.MysD sequence is the sequence shown in SEQ ID NO.44.
[0081] SEQ ID NO.44:
[0082]
[0083] The CDS sequence of Np.MysD-Nl.Loop in the link024-Np.MysD-Nl.Loop sequence is the sequence shown in SEQ ID NO.45.
[0084] SEQ ID NO.45:
[0085]
[0086] The CDS sequence of Nl.MysD-Np.Loop in the link024-Nl.MysD-Np.Loop sequence is the sequence shown in SEQ ID NO.46.
[0087] SEQ ID NO.46:
[0088]
[0089] 5) Results: LC-MS test results are as follows Figure 5 and as shown in Table 1.
[0090] Table 1 Yields of shinorine and porphyra-334 before and after transformation with Np.mysD and Nl.mysD
[0091]
[0092] In Table 1, Np.MysD refers to the detection result of the recombinant plasmid link024-Np.MysD, Np.MysD-Nl.Loop refers to the detection result of the recombinant plasmid link024-Np.MysD-Nl.Loop, Nl.MysD refers to the detection result of the recombinant plasmid link024-Nl.MysD, and Nl.MysD-Np.Loop refers to the detection result of the recombinant plasmid link024-Nl.MysD.
[0093] Figure 5 In the table, NpMysD refers to the detection result of the recombinant plasmid link024-Np.MysD, NpMysD NlLoop refers to the detection result of the recombinant plasmid link024-Np.MysD-Nl.Loop, NlMysD refers to the detection result of the recombinant plasmid link024-Nl.MysD, and NlMysD NpLoop refers to the detection result of the recombinant plasmid link024-Nl.MysD.
[0094] Table 1 and Figure 5 Results showed that the original strain carrying link024-Np.MysD favored shinorine production. However, after replacing the Np.loop with the Nl.loop, the strain carrying link024-Np.MysD-Nl.loop favored porphyra-334 production. The original strain carrying the link024-Nl.MysD plasmid favored porphyra-334 production. However, after replacing the Nl.loop with the Np.loop, the strain carrying link024-Nl.MysD-Np.loop favored shinorine production. This suggests that the 26-amino acid loop region in Np.MysD and Nl.MysD determines their product preference.
[0095] Example 2
[0096] This case identified two key amino acid sites in the omega-loop that determine the specific production of MAAs, including the following steps:
[0097] 1) Exploration of key amino acid sites: To find a more precise production specificity-determining pattern, we narrowed the scope to residues within 5 angstroms of the intermediate and found that only two residues, amino acids L249 and A257 in Np.MysD and amino acids F247 and S255 in Nl.MysD, i.e., the 17th and 25th amino acids in the 26-amino acid loop region, are key amino acid sites that determine the specific production of MAAs.
[0098] 2) Mutation and verification of key amino acid sites: To verify the role of these two residues, we synthesized sequences with one or two key amino acid sites mutated in Np.MysD and Nl.MysD and expressed them in the engineered strain SC.L26. Specifically, the mutation of a single amino acid includes mutating L249 in Np.MysD to F, that is, mutating the 17th amino acid L in Np.loop to F, and the obtained mutant is labeled Np.MysD L249F, and the corresponding plasmid is link024-Np.MysD L249F; mutating A257 in Np.MysD to S, that is, mutating the 25th amino acid A in Np.loop to S, and the obtained mutant is labeled Np.MysD A257S, and the corresponding plasmid is link024-Np.MysD A257S; mutating F247 in Nl.MysD to L, that is, mutating the 17th amino acid F in Nl.loop to L, and the obtained mutant is labeled Nl.MysD F247L, and the corresponding plasmid is link024-Nl.MysD F247L; S255 in Nl.MysD is mutated to A, that is, the 25th amino acid S in Nl.loop is mutated to A, and the obtained mutant is labeled Nl.MysD S255A, and the corresponding plasmid is link024-Nl.MysD S255A; the mutation of two amino acids includes mutating L249 in Np.MysD to F and A257 to S, that is, the 17th amino acid L in Np.loop is mutated to F, and the 25th amino acid A is mutated to S, and the obtained mutant is labeled Np.MysD L249FA257S, and the corresponding plasmid is link024-Np.MysD L249F A257S; F247 in Nl.MysD is mutated to L and S255 is mutated to A, that is, the 17th amino acid F in Nl.loop is mutated to L, and the 25th amino acid S is mutated to A, and the obtained mutant is labeled Nl.MysD F247L S255A, the corresponding plasmid is link024-Nl.MysD F247L S255A.
[0099] The methods for inserting the nucleic acid fragment into the plasmid and for transforming the recombinant plasmid into SC.L26 were the same as in Example 1. The strain was cultured in SC-U medium for two days. The fermentation broth was frozen and thawed twice, then centrifuged and the supernatant was collected. The supernatant was filtered through a 0.22 μm filter and analyzed by LC-MS. Each sample was analyzed in triplicate.
[0100] Among them, the CDS sequence of Np.MysD L249F in the link024-Np.MysD L249F sequence is the sequence shown in SEQ ID NO.47, the CDS sequence of Np.MysD A257S in the link024-Np.MysD A257S sequence is the sequence shown in SEQ ID NO.48, the CDS sequence of Nl.MysD F247L in the link024-Nl.MysD F247L sequence is the sequence shown in SEQ ID NO.49, the CDS sequence of Nl.MysD S255A in the link024-Nl.MysD S255A sequence is the sequence shown in SEQ ID NO.50, the CDS sequence of Np.MysD L249F A257S in the link024-Np.MysD L249F A257S sequence is the sequence shown in SEQ ID NO.51, and the CDS sequence of Np.MysD F247L in the link024-Nl.MysD The CDS sequence of N1.MysD F247L S255A in the S255A sequence is the sequence shown in SEQ ID NO.52.
[0101] SEQ ID NO.47:
[0102]
[0103] SEQ ID NO.48:
[0104]
[0105] SEQ ID NO.49:
[0106]
[0107] SEQ ID NO.50:
[0108]
[0109] SEQ ID NO.51:
[0110]
[0111] SEQ ID NO.52
[0112]
[0113] 3) Results: LC-MS test results are as follows Figure 5 and as shown in Table 2.
[0114] Table 2 Yields of shinorine and porphyra-334 before and after single-site and double-site mutations in Np.mysD and Nl.mysD
[0115]
[0116] In Table 2, Np.MysD L249F is the test result of the recombinant plasmid link024-Np.MysD L249F, and the rest are similar. Figure 5 NpMysD L249F is the test result of the recombinant plasmid link024-Np.MysD L249F, and the rest are similar.
[0117] Table 2 and Figure 5 Our results showed that for the Np.MysD L249F and Nl.MysD F247L single mutants and the Np.MysDL249F A257S and Nl.MysD F247L S255A double mutants, the Np.MysD mutants primarily produced porphyra-334, while the Nl.MysD mutants primarily produced shinorine. However, no changes were observed in Np.MysD A257S and Nl.MysD S255A. Based on the metabolite content produced by wild-type and mutant Np.MysD and Nl.MysD, we demonstrated a pattern whereby MysD favored shinorine production if these two residues were LA or LS, whereas it favored porphyra-334 production if these two residues were FS or FA. This pattern of these two residues could provide guidance for screening for more efficient and specific shinorine or porphyra-334 producers.
[0118] Example 3
[0119] This case further discovered the key amino acid pattern patterns of MysDs, including:
[0120] 1) Homologous Sequence Alignment: To further validate the link between the identity of the two residues on the omega-loop discovered in Example 2 and product specificity, we investigated MysD homologous sequences from other species with different residue patterns. We used BLASTp to query the OrthoDB and NCBI databases using Np.MysD and Nl.MysD as query sequences. We then selected sequences with high similarity for multiple sequence alignment. Based on the two key amino acid residues that determine specific production, we selected 20 loop sequences with similar patterns for testing. Each loop was 26 amino acids long, as shown in Table 3.
[0121] Table 3 MysDs of different patterns obtained by screening
[0122]
[0123]
[0124] 2) Heterologous expression of similar MysDs: MysDs from different species were expressed in SC.L26, and the fermentation supernatants were analyzed for shinorine and porphyra-334 using LC-MS. Insertion of the nucleic acid fragment into the plasmid and transfer of the recombinant plasmid into SC.L26 were performed in the same manner as in Example 1. The strains were cultured in SC-U medium for two days. The fermentation broth was frozen and thawed twice, followed by centrifugation and the supernatant was collected. The supernatant was filtered through a 0.22 μm filter and analyzed by LC-MS. Each sample was analyzed in triplicate.
[0125] Among them, the loop region of Crocosphaera chwakensis CCY0110 is the sequence shown in SEQ ID NO.2, and the MysDs enzyme of Crocosphaera chwakensis CCY0110 is the sequence shown in SEQ ID NO.22; the loop region of Oscillatorianigro-viridis PCC 7112 is the sequence shown in SEQ ID NO.3, and the MysDs enzyme is the sequence shown in SEQ ID NO.23; the loop region of Nostoc sp.ATCC 53789 is the sequence shown in SEQ ID NO.1, and the MysDs enzyme is the sequence shown in SEQ ID NO.24; the loop region of Anabaena sp.90 is the sequence shown in SEQ ID NO.4, and the MysDs enzyme is the sequence shown in SEQ ID NO.25; the loop region of Nostoc sp.KVJ20 is the sequence shown in SEQ ID NO.1, and the MysDs enzyme is the sequence shown in SEQ ID NO.26; the loop region of Anabaena sp.PCC 7108 is the sequence shown in SEQ ID NO. NO.5, and the MysDs enzyme is the sequence shown in SEQ ID NO.27; the loop region of Cyanothece sp.BG0011 is the sequence shown in SEQ ID NO.6, and the MysDs enzyme is the sequence shown in SEQ ID NO.28; the loop region of Coleofasciculus chthonoplastes PCC 7420 is the sequence shown in SEQ ID NO.7, and the MysDs enzyme is the sequence shown in SEQ ID NO.29; the loop region of Microcystis aeruginosa PCC 7806 is the sequence shown in SEQ ID NO.8, and the MysDs enzyme is the sequence shown in SEQ ID NO.30.
[0126] The loop region of Chamaesiphon polymorphus CCALA 037 is shown in SEQ ID NO.10, and the MysDs enzyme is shown in SEQ ID NO.32; the loop region of Chamaesiphon minutus PCC 6605 is shown in SEQ ID NO.11, and the MysDs enzyme is shown in SEQ ID NO.33; the loop region of Nostoc sp.T09 is shown in SEQ ID NO.12, and the MysDs enzyme is shown in SEQ ID NO.34; the loop region of Nostoc linckia z16 is shown in SEQ ID NO.13, and the MysDs enzyme is shown in SEQ ID NO.35; the loop region of Nostoc sp.NIES-4103 is shown in SEQ ID NO.14, and the MysDs enzyme is shown in SEQ ID NO.36; the loop region of Nostoc sphaeroides is shown in SEQ ID NO.15, and the MysDs enzyme is shown in SEQ ID NO.37; The loop region of sp.PA-18-2419 is the sequence shown in SEQ ID NO.16, and the MysDs enzyme is the sequence shown in SEQ ID NO.38; the loop region of Calothrix sp.PCC 6303 is the sequence shown in SEQ ID NO.17, and the MysDs enzyme is the sequence shown in SEQ ID NO.39; the loop region of Calothrix elsteri CCALA 953 is the sequence shown in SEQ ID NO.18, and the MysDs enzyme is the sequence shown in SEQ ID NO.40; the loop region of Gloeocapsa sp.PCC 73106 is the sequence shown in SEQ ID NO.19, and the MysDs enzyme is the sequence shown in SEQ ID NO.41; the loop region of Nostoc commune KU002 is the sequence shown in SEQ ID NO.20, and the MysDs enzyme is the sequence shown in SEQ ID NO.42.
[0127] SEQ ID NO.2: RNHEDKLKKDDSGELTYAAKDKKKAW
[0128] SEQ ID NO.3: RSYADKLKQNDDGNLSLTSKDITKSW
[0129] SEQ ID NO.1:RNYADKLQQTDDGDLHLTAKDNIKAW
[0130] SEQ ID NO.4:RNYADKLQQGDDGNLYLTAKDNIKAW
[0131] SEQ ID NO.1:RNYADKLQQTDDGDLHLTAKDNIKAW
[0132] SEQ ID NO.5:RDYADKLKLGNDGNLFLTAKDNIKAW
[0133] SEQ ID NO.6:RNYEDKLKKDDAGELTYAAKDKKKAW
[0134] SEQ ID NO.7:RNYSDKLKKTETGELTCAAKNNEKAW
[0135] SEQ ID NO.8:RTYADKLKQSQDGSLDCAAKEKTKAW
[0136] SEQ ID NO.10:RRYEDKLGQNQNGDLYMVAKGSTKSW
[0137] SEQ ID NO.11:RRYEDKLGQNKNGDLYMVAKDITRSW
[0138] SEQ ID NO.12:RSYADKLQQTDDGNLGFAAKDNKKSW
[0139] SEQ ID NO.13:RTFADKLKQTDDGNLGFAAKDNKKSW
[0140] SEQ ID NO.14:RIHADKLLQSDDGELRYAAKDNIKSW
[0141] SEQ ID NO.15:RNYVDKLQQTEDGDLSFAAKDNIKSW
[0142] SEQ ID NO.16:RSYADKLIRTDDGNLGYAAKGNKKSW
[0143] SEQ ID NO.17:RSYDDKLKRNEKGDLSAVAKGNTKSW
[0144] SEQ ID NO.18:RSYDDKLKRDENGDLGAVAKGNSKSW
[0145] SEQ ID NO.19:RNYADKLKQTDNGELIFAAKDNGKAW
[0146] SEQ ID NO.20:RNYTDKLQQTEDGDLRFAAKDNIKSW
[0147] SEQ ID NO.22:
[0148] MSVLNILHLVGSAENQFYCDLSRLYAKDCMAATAKPSRYRFFIAYITPDRLWRFPASLSRQDISVAKPLSPSQAIQWITEQNIDLVLPQMFCIPGMTQYRSLFDLLNIPYLGNTAELMALTANKAKAKAIVRSMGVKVPYGELLHKGDTPNLRPPVVIKPDNSDNSLGVTLVKTMDECDTALEKAFEYADQVLVEEYIELGREVRCGTIVKEGELISLPLEEYAVNTENNPIRNHEDKLKKDDSGELTYAAKDKKKAWIVDSNNPVTRRVQEIAKQCHQALGCRHYSLFDFRIDPQGQPWFLEAGLYCSFSPKSVIPMMAQAKGISLNELLEIVIKEAIK
[0149] SEQ ID NO.23:
[0150] MSVLRVLHLVGSAVSDFFCNLSRLYAEDCLKNTANSALYEFHIACISPDRQWRFPTSLDPSAIAAANPMSLAGAVEVLTQLKIDVMVPQMFCIPGMTQYRSLFDMLSIPYVGNPAELMALVADKAKTKAVVAAAGVSVPLGEVVRAGDRLSIDLPVVLKPLNGDNSIGVTLVKNAADYDAALQTALTHSEEVLVEKFIELGREVRCGIIVQAGELVCLPLEEYAVHPDTKPIRSYADKLKQNDDGNLSLTSKDITKSWIVDTSDPITQRVWDRARKCHIALGCRHYSLFDFRIDPHGQPWFLEAGLYCSFAEKSVLSTMVKASGISLDSFFESMLQNALQR
[0151] SEQ ID NO.24:
[0152] MSVLNILHLVGSAHNNFYCDLSRLYAQDCLAATADPSLYNFQIAYITPDRQWRFPDSLSREDIALTKPIPVFDAIQFLTGQNIDMMLPQMFCIPGMTQYRALFDLLKIPYVGNTPDIMAIAAHKARAKAIVEAAGVKVPHGELLCQGDIPTITPPAVVKPVSSDNSLGVVLVKDVTEYDAALKKAFEYADEVIVEAFIELGREVRCGIIVKDGELIGLPLEEYLVDPHDKPIRNYADKLQQTDDGDLHLTAKDNIKAWILDPNDPITEKVQQVAKKCHQALGCRHYSLFDFRIDPKGQPWFLEAGLYCSFSPKSVISSMAKAAGIPLNDLLITAINETLGK
[0153] SEQ ID NO.25:
[0154] MSKLRILHLVGSAHNDFYCNLSRLYAQDCLTGIANQSLYDFEIAYITPDLLWRFPPSLSSEDIAITKPMSLFKAIEFLTARNIDLVLPQMFCIPGMTHYRSLLDLLKIPYIGNTPDIMAITAHKARAKAIVAAAGVKVPRGEILRSGDIPTIKPPAVVKPASSDNSLGVTLVKDATEYETALKTGFEYAKEVIVEEYIELGREVRCGIIVKDGELVGLPLEEYLVNSHKPIRNYADKLQQGDDGNLYLTAKDNIKAWIVNTHDPITQKVQEMAKKCHQALGCRHYSLFDFRIDPNGEPWFLEAGLYCSFAPKSVISSMAKAAGIPLNELLITAINETLG
[0155] SEQ ID NO.26:
[0156] MPVLNILHLVGSAHNNFYCDLSRLYAQDCLTAIADKSLYNFQIAYITPDRQWRFPHSLSREDIALTKPIPLFDAIQFLTGQNIDIMLPQMFCIPGMTQYRALFDLLNIPYIGNTPDIMAIAAHKARAKAIVEAAGVKVPRGELLRQGDIPTITPPVVIKPVSSDNSLGVTLVKEVTEYDAALKKAFEYASEVIVEEFIELGREVRCGIIAKDGELIGLPLEEYLVDPHNKPIRNYADKLQQTDDGDLHLTAKDNIKAWILDPNDPITQKVQEVAKKCHQALGCRHYSLFDFRIDPKGQPWFLEAGLYCSFAPKSVISSMAKAAGIPLNDLLITAINETLGK
[0157] SEQ ID NO.27:
[0158] MSKLDILYLTGSAESDFYCNLSRLYAQDSLTAIEKSNYNIHIAYITPDHQWRFPTSLSPENIAASKPMSLPDAMGLVITKNIDVVLPQMFCIPGMTHFRALFDLLNIPYIGNTPEVMAITANKAKAKAIVASAGVKVPYGEVLRLGDIPTIKPPAVVKPVSSDNSLGVTLVKDIKEYDAALKNAFEYAEEVIVEEYIELGREVRCGIIVKNGELVSLPLEEYLVDSKTKPVRDYADKLKLGNDGNLFLTAKDNIKAWIVDTNDPITQKVQEVAKKCHQALGCRHYSLFDFRIDPNGEPYFLEAGLYCSFAPKSVISSMSKAAGISLNELLEIAINATLSNKKAFRTYALYESAMM
[0159] SEQ ID NO.28:
[0160] MSVLNILHLVGSAENQFYCDLSRLYAKDCIAATAKPSRYRFFIAYITPDRLWRFPASLSRQDISVAKPLSLSQAIQWITEQNIDLALPQMFCVPGMTQYRSLLDLLNIPYLGNTAELMALTANKAKAKAIVRSMGVKVPYGELLRQGDTPNIRPPVVIKPDNSDNSLGVTLVKTMDEYDAGLKKAFEYADQVLVEEYIELGREVRCGTIVKEGELISLPLEEYAVNTENNPIRNYEDKLKKDDAGELTYAAKDKKKAWIVDSNDPVTRRVQEIAKQCHQALGCRHYSLFDFRIDPQGQPWFLEAGLYCSFSPKSVIPMMAEAKGISLDELLEITIKETLK
[0161] SEQ ID NO.29:
[0162] MSVLNILHLVGSAENEFYGDLSRLYAKDCITATANPSRYNFFIAYITPDRLWRFPSSLTPEDIDAAKPISLAEAIQWITTQNIDLVLPQMFCIPGMTHYRGLFDLLNIPYVGNKAELMALTAHKAKAKAIVAAAGVKVPYGELLHQGDTPNLMPPVVIKPANSDNSLGVTLVRNMADYDEALTQAFHYADEVLVEDYIELGREVRCGTFVKNGTLIGLPLEEYSVNTQNHPIRNYSDKLKKTETGELTCAAKNNEKAWIVDTTDPITTKVQDVAKQCHKALGCRHYSLFDFRIDPQGQPWFLEAGLYCSFSPKSVVACMAKAAGISVDELLKTAIAEALI
[0163] SEQ ID NO.30:
[0164] MEKLQILHLVGSAVSDFYCELSRLYAQDCLQNTANPDLYEFHIAYVSPDLRWRFPKSLDNAEIAQTPSVSVPEAVAVLIQLQIDVMVPQMFCLPGMTQYRALFDLLKIPYVGNSAELMALAADKAKAKAVVSAAGVTVPAGKVLHRGDCLSVSRPSIIKPNHSDNSLGLSLVTETTDGDAAFATAFEYADEVLVEEFIELGREVRCGVIVQAGELVCLPLEEYAVNPETHPIRTYADKLKQSQDGSLDCAAKEKTKAWIVDPRDPVTQRVWAIAKQCHVALGCRHYSLFDFRIDPHGQPWFLEAGLYCSFAQKSVISMMAQAAGISLTDLFQNMVQMAVAGEAASFGDRLMIAQIDTKAETYS
[0165] SEQ ID NO.32:
[0166] MMVMRVLHLVGSAVSEFYCDLSRLYARDCLESTANPALYEFHIAYITPDRQWRFPADLSRESIALASPMSVAEAVRVLTALQIDVMVPQMFCIPGMTYYRALFDLLDIPYLGNTPDVMALTANKAKARSIVAAVGVNVPSGELLHPGKQPSTDPPAVIKPVNADNSLGVTLVRNRADYDRALKTAFTYADEVLVETFIELGREVRCGIIDRDGELICLPLEEYKMDKEHQPIRRYEDKLGQNQNGDLYMVAKGSTKSWIVDPDDPITARVWDAAKKCHIALGCRHYSLFDFRIDPSGQPWFLEAGLYCSFASKSVISMMATAADIPLEKLFQIAVNKASLDCHSDRLRQSGAVEGDR
[0167] SEQ ID NO.33:
[0168] MGLRVLHLVGSAVSEFYGDLSRLYAQDCLESTANVQLYEFHIAYITPDRQWRFPADLSREAIALASPMSVAEAVRVLTTLQIDVMVPQMFCIPGMTYYRALFDLLDIPYLGNTPDLMALTANKAKARSIVAAAGVSVPPGELLRIGNRAEPVRIKIDPPAAIKPVDADNSLGVTLVRNRAEYDSALKTAFNYADEVLVETFIELGREVRCGIIDRDGELVCLPLEEYGMDKEHQPIRRYEDKLGQNKNGDLYMVAKDITRSWIVDPDDPITARVWDAAKKCHIALGCRHYSLFDFRIDPSGQPWFLEAGLYCSFASKSVISMMATAADISLEKLFQISVNKALLDCHSDRLR
[0169] SEQ ID NO.34:
[0170] MSVLRILHLVGSAYNDFYCDLSRLYAQDCLTATAERSRYDFLIAYITPDRHWRFPASLSKEDIAIAKPMTLGDAIQFITAQNIDLVLPQMFCIPGMTQYRALFDLLKIPYIGNTSDLMAITAHKARTKAIVAAAGVKVPHGEILRQGEVPTIPPPAIVKPVSSDNSLGVVLVKDVSEYDAALTKAFEYASEVIVEAFIELGREVRCGIFVKDGELVGLPLEEYLVDPHERPIRSYADKLQQTDDGNLGFAAKDNKKSWIVDPSDLITEKVQQVAKKCHQALGCRHYSLFDFRIDPKGQPWFLEAGLYCSFAPKSVISSMAKAVGIPLNELLTIAINEALKTNQNL
[0171] SEQ ID NO.35:
[0172] MPALRILHLVGSAQNDFYCDLSRLYAADCLTATADTFYDFQIAYITPDGQWRFPSSLSREDIAQARPMPLFEAIKLITGQNIDIVLPQMFCIPGMTHYRALFDLLEIPYIGNTPELMAITAHKAKTKAIVEAAGVKVPRGEVLRHGDVPTIAPPVVIKPVSSDNSLGVTLVKDAAEYDAALKTAFEYADEAIVETFIAGREVRCGIIVKDKELIGLPLEEYLLDSHEKPIRTFADKLKQTDDGNLGFAAKDNKKSWIVNPSDPITQKVQEVAKKCHQALGCRHYSLFDFRIDPQGQPWFLEAGLYCSFAPKSVISSMAKAVGISLNELLMIAIDETLGSNKYNLVEVGKF
[0173] SEQ ID NO.36:
[0174] MSVLRILHLVGSADNEFYCNLSRLYAEGCLTATADPSRYDFQIAYITPDRQWRFPRSLSREDIAVSEPISLSEAIELITKQNIDLVLPQMFCIPGMTQYRALFDLLQIPYVGNTADLMAIAAHKARTKAIVEAAGVKVPRGEVLRKGDVPTVTPPAIIKPVSSDNSLGVSLVKEASEYDAALKQAFEYADEVIVETFIEAGREVRCGIIVQDGELVSLPLEEYLLDPQEKPIRIHADKLLQSDDGELRYAAKDNIKSWIVDPKDPITQKVQEVAKKCHQALGCRHYSLFDFRIDPNGQPWFLEAGLYCSFAPKSVISSMAKAAGIPVTELLRTAINETLGSRQKAIA
[0175] SEQ ID NO.37:
[0176] MPVLNILHLVGSAHNDFYCDLSRLYAQDCLAATADSSLYNFQIAYITPDRQWRFPDSLSREDIALTKPIPLFDAIQFLTGQNIDIMLPQMFCIPGMTQYRALFDLLKIPYIGNTPDIMAIAAHKARAKAIVEAAGVKVPRGELLHQGDVPTITPPAVIKPVSSDNSLGVTLVKDVTEYDAALKKAFEYASEVIVEEFIELGREVRCGIIAKDGELIGLPLEEYLVDPHDKPIRNYVDKLQQTEDGDLSFAAKDNIKSWIVDPNDPITEKVQQVAKKCHQALGCRHYSLFDFRIDPKGEPWFLEAGLYCSFAPKSVISSMAKAAGIPLNDLLITAINETLGSNKKALQNILTRD
[0177] SEQ ID NO.38:
[0178] MPVLRILHLVGSAHDDFYCDLSRLYAQECLAATADPSRYDFQIAYITPDGQWRFPRSLSPEDIAEAKPIPLFDAIEFLTGQNIDIMLPHMFCIPGMTHYRALFDLLKIPYIGNTPDLMAITAHKARTKAIVEAAGVKVPHGELLRQGDVSTITPPVIIKPVNSDNSLGVTLVKEATEYDAALKKAFEHASEVIVETFIEVGREVRCGIVVKDGELIGLPLEEYLIDPQEKPIRSYADKLIRTDDGNLGYAAKGNKKSWIVDPNDPSTQKVQEVAKKCHQALGCRHYSLFDFRIDPEGQPWFLEAGLYCSFAHKSVISSMAKVAGIPLHELLIMAINETLGTNK
[0179] SEQ ID NO.39:
[0180] MSVLRVLHLVGSAVDEFYCDLSRLYAQDCLDSTANTELYEFHIAYISPGGTWRFPRDLSSDAIASAEKVSLSGAIQILISLKIDVMLPQMFCVPGMTFYRGLFDLLKIPYIGNTPDVMALAANKAKTKAVVAFSGVSVPQGELLHRGDSPHVTTPAVVKPVDGDNSLGVVLVKNPSDYESALKTAFTHSSEVLVETFIELGREVRCGVIVQDNQLVCLPLEEYQMDKEQQPIRSYDDKLKRNEKGDLSAVAKGNTKSWIVDPSDPITQRVWDVAKKCHIALGCQHYSLFDFRIDPTGKPWFLEAGLYCSFAQISVIPTMAKTSGISLEKLFHIMLNNLLVYSISN
[0181] SEQ ID NO.40:
[0182] MSVLRVLHLVGSAVNEFYSDLSRLYAQDCIKSTANTELYEFHIAYISPDGKWRFPTDLSRDAIALAIPLSLAEAVQVLTALKIDVMLPQMFCVPGMTSYRALFDLLNIPYVGNTPDVMALAANKAKTKAVVGFSGVSVPQGELLRFGDYPKIATPAVVKPVDGDNSLGVVLVKDLSDYESALKTAFAHSSEVLVETFIELGREVRCGVIVEDGELVCLPLEEYLMDKEQQPIRSYDDKLKRDENGDLGAVAKGNSKSWIVDPSDPITARVWDAAKKCHIALNCQHYSLFDFRIDPNGQPWFLEAGLYCSFAQMSVIPTMAKASGIPLDQLFQTMLKNVNLTNKI
[0183] SEQ ID NO.41:
[0184] MSATTILHLVGSAESDFYANLSRLYAKDSLEALNNNPRYNFRIAYITPNRLWRFPSSLSQVDIDSAQPLSIASAVEFLHQQKIDLVLPQMFCLPGMTEYRSLLDLLQIRYIGNPPDVMAIAANKAKTKAIVATAGVKVPKGELLRHSDIPSLKPPVVIKPVNADNSLGVTLVKEKSEYQTALQTAFSYSSEVLVEEYIALGREVRCGIIVKDGELLALPLEEYLVNADNQPIRNYADKLKQTDNGELIFAAKDNGKAWIVDTTDSITPSVQSVAKQCHQALGCRHYSLFDFRIDPLGQPWFLEAGLYCSFSPKSVIVTMAKAAGISLDDLLMNYVLS
[0185] SEQ ID NO.42:
[0186] MPVLNILHLVGSAHNDFYCDLSRLYAQDCLTATADSSLYNFQIAYITPDRQWRFPDSLRREDIALTKPIPLFDAIQFLTVQNFDIMLPQMFCIPGMTQYRALFDLLKIPYIGNTPDIMAIAAHKARAKAIVEAAGVKVPRGELLCQGDVPTITPPAVIKPVSSDNSLGVTLVKDVTEYDAALKKAFEYASEVIVEEFIELGREVRCGIIVKDGELIGLPLEEYLVDPHNKPIRNYTDKLQQTEDGDLRFAAKDNIKSWIVDPNDPITEKVQQVAKKCHQALGCRHYSLFDFRIDPKGQPWFLEAGLYCSFAPKSVISSMAKAAGIPLNDLLITAINETLGSNKKALQN
[0187] 3) Results: The results are shown in Table 4 and Figure 6 as follows.
[0188] Table 4 Yields of shinorine and porphyra - 334 in heterologous expression of MysDs in different modes
[0189]
[0190]
[0191] The names in Table 4 correspond to the "organism name" in Table 3. The content in parentheses after each name is the 17th and 25th amino acids of the corresponding loop. For example, "Crocosphaera chwakensis CCY0110(YA)" means that the loop used is Crocosphaera chwakensis CCY0110, whose 17th and 25th amino acids are Y and A, respectively. Figure 6 The horizontal axis expression of corresponds to the name column in Table 4. Figure 6 Figure (A) summarizes the different MysD production patterns, with the left side indicating a pattern favoring shinorine production and the right side indicating a pattern favoring porphyra-334 production. Figure (B) shows the MAAs production of MysDs with different patterns. One-way ANOVA was performed to compare the shinorine and porphyra-334 levels in different samples. Two samples that do not share the same letter are significantly different from each other (p < 0.05).
[0192] Table 4 and Figure 6 The results show that the 26-amino acid loop can indeed determine whether the product is shinorine or porphyra-334; and, when the 17th and 25th positions are LA or LS, MysD is more likely to produce shinorine, and when the 17th and 25th positions are FS or FA, MysD is more likely to produce porphyra-334. This conclusion is the same as that in Example 2. Furthermore, the 25th amino acid in the loop region is A, and the 17th amino acid is any amino acid except F; or, the 25th amino acid in the loop region is S, and the 17th amino acid is L; such MysD is more likely to produce shinorine. The 25th amino acid in the loop region is S, and the 17th amino acid is any amino acid except L; or, the 25th amino acid in the loop region is A, and the 17th amino acid is F; such MysD is more likely to produce porphyra-334.
[0193] The above content is a further detailed description of the present application in conjunction with specific implementation methods, and the specific implementation of the present application cannot be considered to be limited to these descriptions. For ordinary technicians in the technical field to which the present application belongs, several simple deductions or substitutions can be made without departing from the concept of the present application.
Claims
1. A MysDs enzyme specifically producing mycosporin-like amino acids, characterized in that: The MysDs enzyme contains a loop region of 26 amino acids, and the loop region is of the following two types: The first type of MysDs enzyme: the 25th amino acid in the loop region is A, and the 17th amino acid is any amino acid except F; or, the 25th amino acid in the loop region is S, and the 17th amino acid is L; the first type of MysDs enzyme is used for the specific production of shinorine; The second type of MysDs enzyme: the 25th amino acid in the loop region is S, and the 17th amino acid is any amino acid except L; or, the 25th amino acid in the loop region is A, and the 17th amino acid is F; the second type of MysDs enzyme is used to specifically produce porphyra-334.
2. The MysDs enzyme according to claim 1, characterized in that: The loop region is at least one of SEQ ID NO.1 to SEQ ID NO.20; Wherein, the loop region of the first type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.1 to SEQ ID NO.8; The loop region of the second type MysDs enzyme is at least one of the sequences shown in SEQ ID NO.9 to SEQ ID NO.
20.
3. The MysDs enzyme according to claim 2, characterized in that: The first type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.21 to SEQ ID NO.30; The second type of MysDs enzyme is at least one of the sequences shown in SEQ ID NO.31 to SEQ ID NO.
42.
4. A nucleic acid encoding the MysDs enzyme according to any one of claims 1 to 3.
5. A recombinant plasmid containing the nucleic acid according to claim 4.
6. A microorganism transformed with the recombinant plasmid according to claim 5.
7. The microorganism according to claim 6, characterized in that: The microorganism is a recombinant organism, which is an organism that can produce 4DG using xylose by knocking out endogenous genes and integrating xylose metabolism genes, DDGS genes, and OMT genes into the genome of the organism; Among them, the knocked-out endogenous genes include TAL1 gene and Nqm1 gene, the xylose metabolism genes include xyl1 gene, xyl2 gene and xyl3 gene, and the insertion site of at least one of the xyl1 gene, xyl2 gene and xyl3 gene is the his3 site.
8. The microorganism according to claim 7, characterized in that: Among the xylose metabolism genes, the pTDH3 promoter is used to start the expression of the xyl1 gene, the pPGK1 promoter is used to start the expression of the xyl2 gene, and the pTEF2 promoter is used to start the expression of the xyl3 gene; Preferably, the organism is yeast.
9. Use of the MysDs enzyme according to any one of claims 1 to 3, the nucleic acid according to claim 4, the recombinant plasmid according to claim 5, or the microorganism according to any one of claims 6 to 8 in the specific production of mycosporin-like amino acids.
10. The use according to claim 9, characterized in that: The specific production of mycosporin-like amino acids includes the specific production of shinorine or porphyra-334.
11. A method for specifically producing mycosporin-like amino acids, characterized in that: The method comprises using the MysDs enzyme according to any one of claims 1 to 3, the nucleic acid according to claim 4, the recombinant plasmid according to claim 5 or the microorganism according to any one of claims 6 to 8 to specifically produce shinorine or porphyra-334.
12. The method according to claim 11, characterized in that: The method comprises using the first type of MysDs enzyme in the MysDs enzyme according to any one of claims 1 to 3, or the nucleic acid encoding the first type of MysDs enzyme according to claim 4, or the recombinant plasmid containing the nucleic acid encoding the first type of MysDs enzyme according to claim 5, or the microorganism transformed with the recombinant plasmid containing the nucleic acid encoding the first type of MysDs enzyme according to any one of claims 6 to 8, to specifically produce shinorine; or, The second type of MysDs enzyme among the MysDs enzymes according to any one of claims 1 to 3, or the nucleic acid encoding the second type of MysDs enzyme according to claim 4, or the recombinant plasmid containing the nucleic acid encoding the second type of MysDs enzyme according to claim 5, or the microorganism transformed with the recombinant plasmid containing the nucleic acid encoding the second type of MysDs enzyme according to any one of claims 6 to 8, is used to specifically produce porphyra-334.
Citation Information
Cited By
Strain of high-quality MAAs (maleic anhydride)-producing stellate dichotoma obtained by gamma ray mutation breeding and application of stellate dichotoma
CN122609369A
